Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder
Launched by CENTRAL INSTITUTE OF MENTAL HEALTH, MANNHEIM · Oct 25, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how individuals with Alcohol Use Disorder (AUD) respond to stress and how these responses might affect their cravings for alcohol and their drinking behavior. The research aims to understand the brain and behavior patterns that help some people cope better with stress, which could make them less likely to relapse into drinking. Participants will go through a series of tests, including a stress-inducing activity and being exposed to their favorite alcoholic drink in a controlled setting, while researchers monitor their brain activity and emotional responses using a type of brain scan called fMRI.
To be eligible for this study, participants should be between 16 and 65 years old and meet certain criteria for Alcohol Use Disorder, but they do not need to be currently receiving treatment. They should also be fluent in German and able to understand the study procedures. Participants will use a study smartphone to help track their experiences with stress, cravings, and social interactions in real time. This research is important because it could help develop better ways to support individuals with AUD in managing their stress and reducing their alcohol cravings.
Gender
ALL
Eligibility criteria
- Inclusion criteria are:
- • age between 16 and 65 years
- • meeting at least 2 criteria of an alcohol use disorder according to the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5), yet without the need for a therapeutic intervention
- • fluency in German
- • able to understand the study procedures and give informed consent
- • willingness to use a study smartphone
- Exclusion criteria are:
- • current use of drugs or medications that interact with the central nervous system or the glucocorticoid system
- • contraindications for magnetic resonance imaging
- • medical history of bipolar disorder, psychotic disorder, schizophrenia or schizophrenic spectrum disorder, or substance use disorder other than alcohol, nicotine, or cannabis
- • medical history of severe head injury or other severe central nervous system disorders or other severe somatic disorders (e.g. liver cirrhosis)
- • pregnancy
About Central Institute Of Mental Health, Mannheim
The Central Institute of Mental Health (ZI) in Mannheim is a leading research institution dedicated to advancing the field of mental health through innovative clinical trials and scientific inquiry. With a focus on understanding the complexities of mental disorders, the ZI integrates interdisciplinary approaches to develop effective treatment strategies and improve patient outcomes. The institute is renowned for its state-of-the-art facilities, collaborative research environment, and commitment to ethical standards in clinical research. By fostering partnerships with academic institutions, healthcare providers, and industry stakeholders, the Central Institute of Mental Health aims to translate scientific discoveries into practical applications that enhance mental health care globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mannheim, Baden Württemberg, Germany
Mannheim, , Germany
Patients applied
Trial Officials
Patrick Bach, MD, PhD
Principal Investigator
Central Institute of Mental Health
Falk Kiefer, MD
Principal Investigator
Central Institute of Mental Health
Clemens Kirschbaum, PhD
Principal Investigator
Technical University Dresden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported